文献速递淋巴瘤造血干细胞移植与细胞治疗

不适合自体移植的大B细胞淋巴瘤患者接受CAR-T治疗

CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
PubMed 文献 · Br J Haematol · 2023-04-20

该多中心真实世界队列分析英国国家CAR-T临床小组批准的404例大B细胞淋巴瘤患者,其中81例(20%)不适合自体干细胞移植。不适合移植组从批准到输注的脱落率显著更高(34.6% vs 23.5%,p=0.042),但在已输注患者中两组缓解率、无进展生存和总生存相似,且CAR-T耐受良好。

要点

  • 不适合自体移植组更常接受tisa-cel而非axi-cel(52% vs 48%),适合移植组为20% vs 80%(p<0.0001)。
  • 不适合移植组从批准到输注的脱落率为34.6%,显著高于适合移植组的23.5%(p=0.042)。
  • 已输注患者中,不适合移植组与适合移植组的缓解率、无进展生存和总生存相似。

核心结论

  • CD19 CAR-T可安全用于经过仔细筛选的不适合移植的老年及有合并症的大B细胞淋巴瘤患者。

研究设计与样本

  • 多中心真实世界队列分析,纳入英国国家CAR-T临床小组批准的404例接受axi-cel或tisa-cel治疗的大B细胞淋巴瘤患者,其中81例(20%)被判定不适合自体干细胞移植。

主要发现

  • 不适合移植组接受tisa-cel的比例为52%、接受axi-cel的比例为48%,适合移植组分别为20%和80%(p<0.0001)。
  • 不适合移植组从批准到输注的脱落率为34.6%,适合移植组为23.5%(p=0.042)。
  • 已输注患者中,不适合移植组与适合移植组的缓解率、无进展生存和总生存相似。
  • 不适合移植组≥3级细胞因子释放综合征发生率为2%,≥3级神经毒性发生率为11%。

临床怎么用

  • 作者认为,CD19 CAR-T可安全用于经过仔细筛选的不适合移植的老年及有合并症的大B细胞淋巴瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large B-cell lymphoma (LBCL) patients with comorbidities and/or advanced age are increasingly considered for treatment with CD19 CAR T, but data on the clinical benefit of CAR T in the less fit patient population are still limited. We analysed outcomes of consecutive patients approved for treatment with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) by the UK National CAR T Clinical Panel, according to fitness for autologous stem cell transplant (ASCT). 81/404 (20%) of approved patients were deemed unfit for ASCT. Unfit patients were more likely to receive tisa-cel versus axi-cel (52% vs. 48%) compared to 20% versus 80% in ASCT-fit patients; p < 0.0001. The drop-out rate from approval to infusion was significantly higher in the ASCT-unfit group (34.6% vs. 23.5%; p = 0.042). Among infused patients, response rate, progression-free and overall survival were similar in both cohorts. CAR T was well-tolerated in ASCT-unfit patients with an incidence of grade ≥3 cytokine release syndrome and neurotoxicity of 2% and 11%, respectively. Results from this multicentre real-world cohort demonstrate that CD19 CAR T can be safely delivered in carefully selected older patients and patients with comorbidities who are not deemed suitable for transplant.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kuhnl A, Kirkwood AA, Roddie C, et al. CAR T in patients with large B-cell lymphoma not fit for autologous transplant. Br J Haematol. 2023. PMID: 37082780. doi:10.1111/bjh.18810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。